| FDA-approved medicine (11)Approved for the specific uses on its label, which may not be this goal. |
|---|
| Dulaglutide | REWIND (2019) · Human randomized trial The combined outcome of cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 12.0% with dulaglutide and 13.4% with placebo. Hazard ratio: 0.88 (95% confidence interval 0.79–0.99). Limitation: This was a cardiovascular-risk population with diabetes. The results do not establish a longevity benefit in healthy people. Gastrointestinal events were more frequent with dulaglutide. Studied: 9,901 adults aged 50 or older with type 2 diabetes and cardiovascular disease or risk factors. | FDA-approved | FDA label |
|---|
| Exenatide | EXSCEL (2017) · Human randomized trial The main cardiovascular composite occurred in 11.4% versus 12.2%; hazard ratio 0.91 (95% CI 0.83–1.00). Noninferiority was met, but superiority was not (P=0.06). Limitation: Meeting a cardiovascular safety criterion is different from proving cardiovascular benefit. Results concern the once-weekly preparation and should not be relabeled as an obesity trial. Studied: 14,752 adults with type 2 diabetes. | FDA-approved | FDA label |
|---|
| Glucagon | Nasal versus intramuscular glucagon (2016) · Human randomized crossover trial Success occurred in 98.7% of nasal visits versus 100% of intramuscular visits. Mean recovery times were 16 and 13 minutes, respectively. Limitation: This was a controlled rescue-treatment study, not a comparison of unsupervised use in every emergency. The nasal and injected products have different delivery systems. Studied: 75 adults with type 1 diabetes under supervised experimental hypoglycemia. | FDA-approved | FDA label |
|---|
| Human insulin | DCCT (1993) · Human randomized trial Intensive management reduced development of retinopathy by 76% in the primary-prevention group and slowed progression by 54% in the other group. Severe hypoglycemia was more frequent. Limitation: This tested a treatment strategy including monitoring, not one modern brand versus another. It demonstrates the tradeoff between complication reduction and hypoglycemia risk. Studied: 1,441 people with type 1 diabetes, with or without early retinopathy. | FDA-approved | FDA label |
|---|
| Liraglutide | LEADER (2016) · Human randomized trial The cardiovascular composite occurred in 13.0% versus 14.9%; hazard ratio 0.87 (95% CI 0.78–0.97). Gastrointestinal events were the commonest reason for stopping treatment. Limitation: The 1.9-percentage-point difference describes this population and follow-up. This was not a trial of otherwise healthy people or the separate weight-management product indication. Studied: 9,340 adults with type 2 diabetes and high cardiovascular risk. | FDA-approved | FDA label |
|---|
| Lixisenatide | ELIXA (2015) · Human randomized trial The primary cardiovascular composite occurred in 13.4% with lixisenatide and 13.2% with placebo: hazard ratio 1.02 (95% CI 0.89–1.17). Noninferiority was established; superiority was not. Limitation: The finding supports cardiovascular safety within the trial’s prespecified framework. It does not establish cardiovascular benefit. Heart-failure hospitalization and mortality were not significantly different. Sanofi funded the trial. Studied: 6,068 people with type 2 diabetes and an acute coronary event in the preceding 180 days. | FDA-approved | FDA label |
|---|
| Orforglipron | ATTAIN-1: orforglipron versus placebo for 72 weeks in adults with obesity (2025) · Human randomized phase 3 trial Counting everyone randomized, average weight change at 72 weeks was -7.5%, -8.4% and -11.2% across the three dose levels versus -2.1% with placebo. On the highest dose, 54.6% lost at least 10% of their weight and 18.4% lost at least 20%. Waist size, blood pressure, triglycerides and non-HDL cholesterol also improved. Limitation: The trial was funded by Eli Lilly, lasted 72 weeks and measured weight and risk factors, not heart attacks, strokes or deaths. No trial has compared orforglipron directly with injectable semaglutide or tirzepatide for weight loss, and results from separate trials are not a direct contest. Studied: 3,127 adults with obesity, or overweight with a weight-related condition, without diabetes. | FDA-approved | FDA label |
|---|
| Semaglutide | STEP 1 (2021) · Human randomized trial Mean weight change was −14.9% versus −2.4%, a 12.4-percentage-point estimated difference. Gastrointestinal effects were common. Limitation: These are average results for a specific injectable regimen and trial population. The study is not a comparison with tirzepatide and cannot validate compounded or research-use products. Studied: 1,961 adults with obesity, or overweight with a weight-related condition, without diabetes. | FDA-approved | FDA label |
|---|
| Setmelanotide | Setmelanotide in POMC or LEPR deficiency (2020) · Human open-label phase 3 studies with withdrawal periods At least 10% weight loss was reported in 8 of 10 POMC participants and 5 of 11 LEPR participants. Limitation: This was not a full-year parallel placebo-controlled comparison. Small, genetically selected cohorts do not establish effectiveness in common obesity. Studied: 10 participants with POMC deficiency and 11 with LEPR deficiency, aged six years or older. | FDA-approved | FDA label |
|---|
| Tesamorelin | HIV-associated abdominal-fat trial (2007) · Human randomized trial Visceral fat decreased 15.2% with tesamorelin and increased 5.0% with placebo. Some lipid measures also improved. IGF-I increased by 81.0% versus a 5.0% decrease with placebo. More tesamorelin recipients withdrew because of adverse events, despite no significant overall adverse-event difference. Limitation: Visceral-fat change is not the same as total body-weight loss. The trial population and HIV-associated condition are central; long-term cardiovascular benefit was not established by this endpoint. Studied: 412 people with HIV and abdominal fat accumulation; 86% were men. | FDA-approved | FDA label |
|---|
| Tirzepatide | SURMOUNT-1 (2022) · Human randomized trial Mean weight reductions were 15.0%, 19.5%, and 20.9% across active groups versus 3.1% with placebo. Gastrointestinal effects were common. Limitation: This trial cannot be compared directly with STEP 1 as if participants were randomized between the two drugs. Outcomes depend on population, duration, regimen, and handling of discontinuation. Studied: 2,539 adults with obesity, or overweight and a weight-related complication, without diabetes. | FDA-approved | FDA label |
|---|
| Randomized human trials (13)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition. |
|---|
| Cagrilintide | Cagrilintide dose-finding study (2021) · Human phase 2 randomized trial Estimated mean weight reduction ranged from 6.0% to 10.8% across cagrilintide groups versus 3.0% with placebo in the trial-product analysis. Gastrointestinal and injection-site events were frequent. Limitation: This is monotherapy evidence. It cannot be presented as the result for CagriSema or for an unidentified seller blend; longer-term outcomes require separate studies. Studied: 706 adults with obesity, or overweight with hypertension or dyslipidemia, without diabetes. | Not approved | Trials only |
|---|
| Efpeglenatide | AMPLITUDE-O (2021) · Human randomized trial Major cardiovascular events occurred in 7.0% versus 9.2%: hazard ratio 0.73 (95% CI 0.58–0.92). The renal composite occurred in 13.0% versus 18.4%: hazard ratio 0.68. Limitation: These are findings in people with diabetes and elevated risk, not a longevity trial in healthy adults. Composite endpoints must be read with their component definitions. Sanofi funded the study. Studied: 4,076 adults with type 2 diabetes and cardiovascular disease, or kidney disease plus an additional cardiovascular risk factor. | Not approved | Trials only |
|---|
| Eloralintide | 48-week phase 2 trial in adults with obesity or overweight (2025) · Human randomized phase 2 trial Average weight change at 48 weeks ranged from about -9% in the lowest dose group to about -20% in the highest groups, versus -0.4% with placebo, and weight loss rose with dose. The most common side effects were nausea (11% to 64% across dose groups, versus 14% with placebo) and fatigue (0% to 46%, versus 12%); both were more common in the higher dose groups than in the lowest ones, though not in a steady pattern. Limitation: One 48-week phase 2 trial of 263 people, run and funded by the manufacturer. It does not show effects on heart disease, long-term safety or whether the weight stays off, and it did not compare eloralintide with GLP-1 drugs or with cagrilintide. Phase 3 results are not expected until about 2028. Studied: 263 adults aged 18 to 75 at 46 US research centers with a BMI of 30 or more, or 27 or more with at least one weight-related condition, and… | Not approved | Trials only |
|---|
| Ghrelin | Ghrelin infusion and food intake (2001) · Human randomized crossover study Energy intake was approximately 28% higher after ghrelin, and appetite ratings increased. The tested gastric-emptying measure did not change. Limitation: An acute study in nine healthy people does not establish a chronic disease benefit, sustained weight change, or effects in cachexia. Studied: Nine healthy volunteers. | Not approved | Trials only |
|---|
| L-Carnosine | Carnosine in overweight and obese adults (2016) · Human randomized pilot trial The supplemented group showed attenuation of increases in fasting insulin and insulin resistance. A subgroup analysis reported glucose-tolerance changes. Limitation: Small pilot and subgroup findings do not establish prevention of type 2 diabetes or treatment of neurological disease. Studied: 30 overweight or obese adults without diabetes. | Not approved | Trials only |
|---|
| Mazdutide | GLORY-1 (2025) · Human randomized trial At week 32, mean weight change was −10.09% and −12.55% in the mazdutide groups versus +0.45% with placebo. At week 48, the corresponding changes were −11.00%, −14.01%, and +0.30%. Limitation: The study population and analysis are specific to this trial. It was not a head-to-head comparison with semaglutide or tirzepatide. The trial was funded by Innovent. Studied: 610 Chinese adults aged 18–75 with obesity, or overweight and an associated condition. | Not approved | Trials only |
|---|
| MK-677 | Ibutamoren in healthy older adults (2008) · Human randomized trial Fat-free mass increased with ibutamoren versus placebo, but strength and function did not improve. Fasting glucose increased and insulin sensitivity decreased. Limitation: More fat-free mass does not establish stronger muscles, improved independence, or a longevity benefit. Studied: 65 healthy adults aged 60–81. | Not approved | Trials only |
|---|
| Pemvidutide | IMPACT (2025) · Human randomized trial MASH resolution without worsening fibrosis occurred in 58% and 52% of the pemvidutide groups versus 20% with placebo. Fibrosis improvement without worsening MASH was 33% and 36% versus 28%; these fibrosis comparisons were not statistically significant. Limitation: Short-term biopsy outcomes are different from cirrhosis prevention, transplantation, or survival. A positive MASH-resolution result does not turn the nonsignificant fibrosis outcome into a proven benefit. Altimmune funded the trial. Studied: 212 adults with biopsy-confirmed MASH and F2 or F3 fibrosis. | Not approved | Trials only |
|---|
| Peptide YY | PYY3-36 with and without GLP-1 (2014) · Human randomized crossover study Neither individual infusion significantly reduced food intake in this experiment. The combination reduced intake by 30.4%; nausea increased slightly. Limitation: An acute combined-hormone effect cannot be transferred to PYY alone or interpreted as sustained weight loss. Studied: 25 overweight healthy men. | Not approved | Trials only |
|---|
| Pramlintide | Adjunct-to-insulin trial (2006) · Human randomized trial HbA1c declined by 0.5 percentage points in both groups. Weight changed by −1.3 kg with pramlintide versus +1.2 kg with placebo. Post-meal glucose excursions improved more with pramlintide. Nausea occurred in 63% versus 36%; severe hypoglycemia event rates were 0.57 versus 0.30 per patient-year. Limitation: The glucose-management protocol included clinician-directed insulin adjustment. A favorable meal-glucose finding should not be described as superior HbA1c reduction or used as a self-treatment protocol. Studied: 296 people with type 1 diabetes. | Withdrawn | FDA label |
|---|
| Retatrutide | Triple-receptor obesity trial (2023) · Human phase 2 randomized trial At 48 weeks, average weight reduction reached 24.2% in the highest studied group versus 2.1% with placebo. Gastrointestinal events and dose-related heart-rate increases were reported. Limitation: This early efficacy trial does not establish long-term outcomes or verify commercial “R” products. Study doses describe the trial, not instructions for using research chemicals. Studied: 338 adults with obesity, or overweight with a weight-related condition. | Not approved | Trials only |
|---|
| Survodutide | SYNCHRONIZE-1 (2026) · Human randomized trial Mean weight changes in the treatment-regimen analysis were −12.2% and −13.0% versus −5.4% with placebo. Gastrointestinal adverse events occurred in 80.9%, 89.7%, and 47.9%, respectively. Limitation: The analysis included treatment discontinuation and other weight-management interventions. Its percentages should not be mixed with results using different estimands. Boehringer Ingelheim funded the study. Studied: 725 adults without diabetes who had obesity, or overweight with an associated condition. | Not approved | Trials only |
|---|
| UBT251 | 24-week phase 2 trial in adults with overweight or obesity in China (2026) · Human randomized phase 2 trial Average weight change at 24 weeks ranged from about -13.6% to -19.7% across UBT251 dose groups, versus -2.0% with placebo; after subtracting the placebo result, the differences were about 11.5 to 17.7 percentage points. Waist size, BMI, blood pressure, blood fats and blood sugar measures also improved. The most frequent side effects were mild to moderate digestive symptoms. Limitation: One 24-week phase 2 trial of 205 people in China, run and funded by the developer. It is too short to show whether weight loss continues or is maintained, it did not compare UBT251 with approved drugs, and it cannot show effects on heart disease or long-term safety. Phase 3 trials registered in 2026 had not reported results when this page was checked. Studied: 205 adults aged 18 to 61 with overweight or obesity and without type 2 diabetes, at multiple research centers in China; 59% women. | Not approved | Trials only |
|---|
| Small or uncontrolled human studies (1)Human reports without randomization, such as pilots, case series or open-label studies. |
|---|
| Nisotirostide | Discovery-to-clinic phase 1 study (2026) · Human phase 1 study with separate preclinical experiments Mean weight difference versus placebo was −0.75 kg with nisotirostide alone, which was not statistically significant. Added to dulaglutide, a difference of up to −2.58 kg versus dulaglutide alone was reported (P<0.05). Nausea and vomiting were the most common adverse events, described as dose-dependent and mild to moderate. Limitation: Small, early, single-administration research cannot establish sustained effectiveness or long-term safety. Follow-up duration, subgroup sizes, confidence intervals, and detailed allocation methods are not supplied in the abstract. A pharmacokinetic rationale for weekly development is not an established treatment schedule. Studied: 65 participants in the phase 1 study, including healthy participants and participants with type 2 diabetes already receiving dulaglutide.… | Not approved | Very limited |
|---|
| Animal and lab studies only (9)No human study in our sources. |
|---|
| 5-Amino-1MQ | See the profile for the animal and lab research. | Not approved | None |
|---|
| Adipotide | See the profile for the animal and lab research. | Not approved | None |
|---|
| AOD-9604 | See the profile for the animal and lab research. | Not approved | Very limited |
|---|
| HGH Fragment 176-191 | See the profile for the animal and lab research. | Not approved | None |
|---|
| MOTS-c | See the profile for the animal and lab research. | Not approved | None |
|---|
| Nesfatin-1 | See the profile for the animal and lab research. | Not approved | None |
|---|
| Neuropeptide Y | See the profile for the animal and lab research. | Not approved | Very limited |
|---|
| Orexin-A | See the profile for the animal and lab research. | Not approved | Very limited |
|---|
| SLU-PP-332 | See the profile for the animal and lab research. | Not approved | None |
|---|